-
Now1. CiPA Technical Services
2. HiPSC-2D cell products
Cardiosight®
Neurosight®
Hepatosight®
3. HiPSC-3D organoid products
Cardiac organoid®
Heart organoid®
4. CDMO (hiPSC customized differentiation service)
5. Drug toxicity, -> 、Security evaluation service
-
Extend1. HiPSC-2D Cell Product Expansion
Diversified neural cells
2. Commercial use of MICRO organoids
3. Develop a drug efficacy evaluation platform
Nafld
Autism
Parkinson
Degenerative brain disease
-
Future1. HiPSC-2D cell & 3D organoid product expansion
Skin
Lungs
Intestines
2. Expansion of Drug Toxicity and Efficacy Evaluation Platform
3. Develop a new efficiency evaluation platform
Cosmetics
Health products
Intestinal microbiota products
Company Profile
- 1
The only hiPSC derived cardiomyocyte product in China to participate in the revision of ICH guidelines
- 3
HESI Heart Safety Committee verifies that the most suitable product for heart safety evaluation among 3 similar products
- 28
CiPA requires testing of 28 high/medium/low-risk drugs
- 200+
Having experience in producing over 200 human induced stem cell (hiPSC) lines
- 2019year
Team joins HESI and participates in the revision of ICH guidelines
- 2023year
The new ICH Guiding Principles (CiPA) have been implemented in China.
Company Strategy
Development History
Our Team
Zhu Shifeng MS, CEO
I have worked in the field of pharmaceutical research and development for over 20 years, with rich experience in new drug development
Vice General Manager of Yanbian University Caoxian Pharmaceutical Co., Ltd
Head of R&D Department, Caoxian Pharmaceutical Co., Ltd., Yanbian University
Master's degree from the School of Pharmacy, Yanbian University
Han Dongxu PhD, CTO
Research in the field of stem cells and organoids for over 20 years
Professor at Korea National University
Distinguished Professor at Wuyi University
Haier International Cell Bank Technology Consultant
Technical Consultant of Qilu Hospital Regeneration and Restoration Medical Center
Associate Member of the Korean Academy of Science and Technology (KAST)
Founding member of Y-KAST
- Published over 126 papers in Cell, Nature, and other journals
- Patents: 25
- Technology transfer: 7 items
Li Jiang BS, CMO
Over 20 years of management and marketing experience in the pharmaceutical industry
Regional Manager of Caoxian Pharmaceutical, Yanbian University
General Manager of Dalian Boya Medical Equipment Co., Ltd
With over 20 years of experience in the sales of drugs and medical devices, I have rich marketing experience.
Jin Xiong PhD, CBO
More than 10 years in the fields of cell biology and big data analysis
Henan University's "Outstanding Talents Special Zone Support Program" Yellow River Scholar Distinguished Professor
South Korean NEXEL New Drug R&D Team Leader/Senior Researcher and Technical Advisor for China Region
Professor at the Institute of Animal Molecular Bioengineering, Goryeo University, South Korea
Jin Zhelung PhD, R&D Director
More than 5 years in the field of stem cells and organoids
R&D team leader of Organ Factory, an organoid company
Postdoctoral Fellow at Wuyi University
PhD from Chungbuk National University in South Korea
Science Consultant
-
Professor Tobias Cantz
Associate Professor of Translational Hepatology and Stem Cell Biology at Hanover Medical School
Deputy Director of Translational Regenerative Medicine Center
Head of the Ethics, Legal, and Social Aspects Group at the German Stem Cell Network
-
Professor Kee-Pyo Kim
Associate Professor, School of Medicine, Catholic University of Korea
Scientist at Max Planck Institute for Molecular Biomedical Research
Postdoctoral researcher at Baylor College of Medicine
Postdoctoral scholar at the University of California, Los Angeles
-
Professor Johnny Kim
Director of TRON Cardiology, affiliated research institute of BioNtech, Germany
Associate Professor at Yale University School of Medicine in the United States
Leader of the Max Planck Institute for Cardiopulmonary Research in Germany
